Celia C Kamath1,2,3, Claudia C Dobler4, Rozalina G McCoy5,6,7, Michelle A Lampman5,6, Atieh Pajouhi7, Patricia J Erwin8, John Matulis7, Muhamad Elrashidi7, Joseph Darcel9, Mouaz Alsawas4, Zhen Wang4, Nilay D Shah5,6, M Hassan Murad4, Bjorg Thorsteinsdottir5,6,10. 1. Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN, USA. kamath.celia@mayo.edu. 2. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. kamath.celia@mayo.edu. 3. Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN, USA. kamath.celia@mayo.edu. 4. Evidence-Based Practice Center, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. 5. Division of Health Care Policy and Research, Mayo Clinic, Rochester, MN, USA. 6. Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN, USA. 7. Division of Community Internal Medicine, Mayo Clinic, Rochester, MN, USA. 8. Mayo Clinic Libraries, Mayo Clinic, Rochester, MN, USA. 9. University of Manitoba, Winnipeg, Canada. 10. Knowledge and Evaluation Research Unit, Mayo Clinic, Rochester, MN, USA.
Abstract
INTRODUCTION: Chronic kidney disease (CKD) is widely prevalent, associated with morbidity and mortality, but may be lessened with timely implementation of evidence-based strategies including blood pressure (BP) control. Nonetheless, an evidence-practice gap persists. We synthesize the evidence for clinician-facing interventions to improve hypertension management in CKD patients in primary care. METHODS: Electronic databases and related publications were queried for relevant studies. We used a conceptual model to address heterogeneity of interventions. We conducted a quantitative synthesis of interventions on blood pressure (BP) outcomes and a narrative synthesis of other CKD relevant clinical outcomes. Planned subgroup analyses were performed by (1) study design (randomized controlled trials (RCTs) or nonrandomized studies (NRS)); (2) intervention type (guideline-concordant decision support, shared care, pharmacist-facing); and (3) use of behavioral/implementation theory. RESULTS: Of 2704 manuscripts screened, 73 underwent full-text review; 22 met inclusion criteria. BP target achievement was reported in 15 and systolic BP reduction in 6 studies. Among RCTs, all interventions had a significant effect on BP control, (pooled OR 1.21; 95% CI 1.07 to 1.38). Subgroup analysis by intervention type showed significant effects for guideline-concordant decision support (pooled OR 1.19; 95% CI 1.12 to 1.27) but not shared care (pooled OR 1.71; 95% CI 0.96 to 3.03) or pharmacist-facing interventions (pooled OR 1.04; 95% CI 0.82 to 1.34). Subgroup analysis finding was replicated with pooling of RCTs and NRS. The five contributing studies showed large and significant reduction in systolic BP (pooled WMD - 3.86; 95% CI - 7.2 to - 0.55). Use of a behavioral/implementation theory had no impact, while RCTs showed smaller effect sizes than NRS. DISCUSSION: Process-oriented implementation strategies used with guideline-concordant decision support was a promising implementation approach. Better reporting guidelines on implementation would enable more useful synthesis of the efficacy of CKD clinical interventions integrated into primary care. PROSPERO REGISTRATION NUMBER: CRD42018102441.
INTRODUCTION: Chronic kidney disease (CKD) is widely prevalent, associated with morbidity and mortality, but may be lessened with timely implementation of evidence-based strategies including blood pressure (BP) control. Nonetheless, an evidence-practice gap persists. We synthesize the evidence for clinician-facing interventions to improve hypertension management in CKD patients in primary care. METHODS: Electronic databases and related publications were queried for relevant studies. We used a conceptual model to address heterogeneity of interventions. We conducted a quantitative synthesis of interventions on blood pressure (BP) outcomes and a narrative synthesis of other CKD relevant clinical outcomes. Planned subgroup analyses were performed by (1) study design (randomized controlled trials (RCTs) or nonrandomized studies (NRS)); (2) intervention type (guideline-concordant decision support, shared care, pharmacist-facing); and (3) use of behavioral/implementation theory. RESULTS: Of 2704 manuscripts screened, 73 underwent full-text review; 22 met inclusion criteria. BP target achievement was reported in 15 and systolic BP reduction in 6 studies. Among RCTs, all interventions had a significant effect on BP control, (pooled OR 1.21; 95% CI 1.07 to 1.38). Subgroup analysis by intervention type showed significant effects for guideline-concordant decision support (pooled OR 1.19; 95% CI 1.12 to 1.27) but not shared care (pooled OR 1.71; 95% CI 0.96 to 3.03) or pharmacist-facing interventions (pooled OR 1.04; 95% CI 0.82 to 1.34). Subgroup analysis finding was replicated with pooling of RCTs and NRS. The five contributing studies showed large and significant reduction in systolic BP (pooled WMD - 3.86; 95% CI - 7.2 to - 0.55). Use of a behavioral/implementation theory had no impact, while RCTs showed smaller effect sizes than NRS. DISCUSSION: Process-oriented implementation strategies used with guideline-concordant decision support was a promising implementation approach. Better reporting guidelines on implementation would enable more useful synthesis of the efficacy of CKD clinical interventions integrated into primary care. PROSPERO REGISTRATION NUMBER: CRD42018102441.
Authors: Bharati Bhardwaja; Nikki M Carroll; Marsha A Raebel; Elizabeth A Chester; Eli J Korner; Bob E Rocho; David W Brand; David J Magid Journal: Pharmacotherapy Date: 2011-04 Impact factor: 4.705
Authors: Andrew S Levey; Anton C Schoolwerth; Nilka Ríos Burrows; Desmond E Williams; Karma Rabon Stith; William McClellan Journal: Am J Kidney Dis Date: 2009-03 Impact factor: 8.860
Authors: Josef Coresh; Elizabeth Selvin; Lesley A Stevens; Jane Manzi; John W Kusek; Paul Eggers; Frederick Van Lente; Andrew S Levey Journal: JAMA Date: 2007-11-07 Impact factor: 56.272
Authors: Ayub Akbari; Peter J Swedko; Heather D Clark; William Hogg; Jacques Lemelin; Peter Magner; Lisa Moore; Daylily Ooi Journal: Arch Intern Med Date: 2004-09-13
Authors: Paul E Drawz; R Tyler Miller; Simran Singh; Brook Watts; Elizabeth Kern Journal: BMC Med Inform Decis Mak Date: 2012-07-05 Impact factor: 2.796
Authors: Simon de Lusignan; Simon de Lusignana; Hugh Gallagher; Simon Jones; Tom Chan; Jeremy van Vlymen; Aumran Tahir; Nicola Thomas; Neerja Jain; Olga Dmitrieva; Imran Rafi; Andrew McGovern; Kevin Harris Journal: Kidney Int Date: 2013-03-27 Impact factor: 10.612
Authors: Florian R Schroeck; A Aziz Ould Ismail; David A Haggstrom; Steven L Sanchez; DeRon R Walker; Lisa Zubkoff Journal: Implement Sci Date: 2022-09-01 Impact factor: 7.960